Back to Journals » Neuropsychiatric Disease and Treatment » Volume 17

Comparative Study of the Effects of Atypical Antipsychotic Drugs on Plasma and Urine Biomarkers of Oxidative Stress in Schizophrenic Patients

Authors Dietrich-Muszalska A, Kolodziejczyk-Czepas J, Nowak P

Received 5 November 2020

Accepted for publication 20 January 2021

Published 17 February 2021 Volume 2021:17 Pages 555—565

DOI https://doi.org/10.2147/NDT.S283395

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Dr Roger Pinder


Anna Dietrich-Muszalska,1 Joanna Kolodziejczyk-Czepas,2 Pawel Nowak2

1Medical University of Lodz, Department of Biological Psychiatry and Neurophysiology, Lodz, Poland; 2University of Lodz, Department of General Biochemistry, Lodz, Poland

Correspondence: Anna Dietrich-Muszalska
Department of Biological Psychiatry and Neurophysiology Medical University of Lodz, Lodz, 92-215, Poland
, Mazowiecka 6/8 Tel +691881787
Fax +48 42 2725652
Email tzn_lodz@post.pl

Purpose: Evidence that antipsychotic drugs (ADs) can affect oxidative stress estimated with various biomarkers in schizophrenic patients is controversial and limited. Therefore, in the present study, we assessed the ability of six atypical ADs (clozapine, olanzapine, quetiapine, risperidone, aripiprazole, and ziprasidone) used in schizophrenia treatment to modulate oxidative damage to different biomolecules such as lipids and proteins.
Patients and Methods: We measured the levels of oxidative stress markers in plasma and urine: total antioxidant capacity by FRAP (according to a modified method of Benzie & Strain), thiobarbituric acid reactive species – TBARS (spectrophotometric method), 4-hydroxy-2-nonenal (4-HNE) (OxiSelect™ HNE Adduct Competitive ELISA Kit), 3-nitrotyrosine (3-NT) (OxiSelect™ Nitrotyrosine ELISA Kit) in plasma, and F2-isoprostanes (BIOXYTECH® Urinary 8-epi-Prostaglandin F2α) in the urine of 60 schizophrenic patients (before and after treatment) and in 30 healthy subjects.
Results: Our results showed that in schizophrenic patients levels of lipid peroxidation markers (TBARS, F2-isoprostanes) were higher than in healthy subjects but FRAP in schizophrenic patients was lower than in healthy controls and increased after 4-week treatment with tested ADs. A 4-week treatment with ADs caused the improvement of psychopathology symptoms estimated by Positive and Negative Syndrome Scale (PANSS) that was accompanied by decreased lipid peroxidation (F2-isoprostanes, TBARS; p=2.9x10− 6, p=7.6x10− 5, respectively) and an increase in total antioxidative capacity (FRAP) (p=5.16x10− 16).
Conclusion: Atypical antipsychotics especially clozapine, olanzapine and quetiapine demonstrate the effective outcome of antipsychotic treatment, beneficial antioxidative action by reducing lipid peroxidation and increased total plasma antioxidant activity.

Keywords: schizophrenia, antipsychotics, F2-isoprostanes, TAC, other oxidative markers

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]